Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 - CEO Geert Cauwenbergh to Retire and Remain on Board of Directors - PR Newswire MARLBOROUGH...
RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights - Appoints Gerrit Dispersyn as President and Chief Operating Officer, effective Today - Geert...
RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018 PR Newswire MARLBOROUGH, Mass., Nov. 7, 2018...
RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018 PR Newswire MARLBOROUGH, Mass., Nov. 6, 2018 MARLBOROUGH, Mass., Nov. 6, 2018 /PRNewswire/...
RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering PR Newswire MARLBOROUGH, Mass., Oct. 3, 2018 MARLBOROUGH, Mass., Oct. 3, 2018 /PRNewswire/ -- RXi...
RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering PR Newswire MARLBOROUGH, Mass., Oct. 1, 2018 MARLBOROUGH, Mass., Oct. 1, 2018 /PRNewswire/ -- RXi...
RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on...
RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference - Conference to be held September 4-6, 2018 in NYC - RXi to webcast presentation on September...
RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of...
RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights - Extended cash runway by securing net proceeds of $4.2 million in April 2018 - Announced...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.